Medigene AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Medigene AG completes capital increase announced for funding of cancer immunotherapy programmes
Medigene AG:Says completes capital increase announced on June 27, for funding of cancer immunotherapy programmes.Says gross proceeds of 15.9 million euros were achieved by placing maximum number of new shares and issuance of convertible bonds.Says issues 3.02 million new shares from authorised capital, share capital of Medigene AG increases by 3.02 million euros from 10.89 million euros to 13.9 million euros.Says issues convertible bonds divided into 818,658 notes in the nominal amount of 1.00 euro per note.
Latest Key Developments in Pharmaceuticals
- Alimera Sciences' Iluvien receives marketing authorization in Norway for the treatment of chronic diabetic macular edema
- AB Science announces publication of results from randomized phase 2 study of masitinib
- R&I affirms Eisai Co Ltd's rating at "AA-" and announces negative outlook
- Retrophin Inc proposes acquisition of Clinuvel Pharmaceuticals
- Share this
- Digg this